Respiratory syncytial virus infections in children with acute myeloid leukemia: A report from the Children's Oncology Group
- 9 October 2008
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 51 (6) , 784-786
- https://doi.org/10.1002/pbc.21710
Abstract
Background Morbidity and mortality related to respiratory syncytial virus (RSV) in pediatric acute myeloid leukemia (AML) is not known. Procedure We combined data from three Children's Oncology Group AML studies and determined the prevalence of RSV infection and RSV‐related mortality in children treated for de novo AML. Results We found that the prevalence of RSV infection ranged from 0% to 1% in induction and between 0.3 and 2.2% in consolidation. Four children died from RSV resulting in RSV‐specific mortality of 0.2% among all children. However, the risk of RSV‐related mortality among RSV infection episodes was high (4/40, 10%). Conclusions RSV infections and deaths are rare in pediatric AML. Pediatr Blood Cancer 2008;51:784–786.Keywords
This publication has 13 references indexed in Scilit:
- Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology GroupBlood, 2008
- Immunoglobulin treatment for respiratory syncytial virus infectionPublished by Wiley ,2006
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer GroupBlood, 2001
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart diseaseThe Journal of Pediatrics, 1998
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasiaThe Pediatric Infectious Disease Journal, 1998
- Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin ProphylaxisPediatrics, 1997
- Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young ChildrenNew England Journal of Medicine, 1993